Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Revenue of Pharma Mar, S.A. (PHM.MC)
Revenue in 2023 (TTM): $171.12 M
According to Pharma Mar, S.A.'s latest financial reports the company's current revenue (TTM) is $171.12 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Pharma Mar, S.A.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $171.12 M | $156.74 M | $439.29 K | $-3,920,063 | $1.23 M |
| 2022 | $212.44 M | $197.68 M | $58.77 M | $47.38 M | $53.4 M |
| 2021 | $248.68 M | $230.89 M | $112.5 M | $102.93 M | $100.47 M |
| 2020 | $292.1 M | $277.25 M | $169.02 M | $157.54 M | $148.52 M |
| 2019 | $92.86 M | $87.2 M | $-12,380,173 | $-23,429,493 | $-9,932,703 |
| 2018 | $175.46 M | $136.65 M | $-7,802,257 | $-20,237,612 | $-5,988,836 |
| 2017 | $194.04 M | $144.63 M | $-11,552,448 | $-24,734,378 | $-28,937,924 |
| 2016 | $195.78 M | $148.2 M | $-12,634,441 | $-26,724,164 | $-26,056,574 |
| 2015 | $208.62 M | $159.17 M | $19.14 M | $6.49 M | $7.13 M |
| 2014 | $160.88 M | $123.24 M | $28.2 M | $15.66 M | $14.19 M |
| 2013 | $151.99 M | $115.73 M | $26.78 M | $14.93 M | $12.25 M |
| 2012 | $149.56 M | $110.19 M | $23.22 M | $10.2 M | $7.13 M |
| 2011 | $164.99 M | $121.69 M | $14.87 M | $1.23 M | $-1,485,577 |
| 2010 | $166.09 M | $116.31 M | $-4,528,144 | $-15,744,092 | $-13,343,147 |
| 2009 | $133.5 M | $85.95 M | $-29,206,258 | $-28,368,795 | $-30,442,977 |
| 2008 | $113.89 M | $71.6 M | $-35,139,912 | $-46,515,995 | $-47,323,162 |
| 2007 | $92.47 M | $51.12 M | $-49,046,778 | $-50,845,052 | $-54,819,215 |
| 2006 | $82.49 M | $46.35 M | $-45,595,218 | $-52,636,833 | $-52,636,833 |
| 2005 | $509.62 K | $509.62 K | $6.27 M | $-3,268,703 | $45.44 K |
| 2004 | $723.85 K | $723.85 K | $2.88 M | $-2,207,267 | $1.48 M |
| 2003 | $86.92 M | $45.22 M | $-24,208,529 | $-31,403,787 | $-28,374,205 |
| 2002 | $71.28 M | $35.57 M | $-44,308,727 | $-47,193,323 | $-38,146,773 |